Abnormal levels (high/low) of urinary human serum albumin
(HSA)
are associated with a number of diseases and thus act as an essential
biomarker for quick therapeutic monitoring and biomedical diagnosis,
entailing the urgent development of an effective chemosensor to quantify
the albumin levels. Herein, we have rationally designed and developed
a small fluorogenic molecular probe, (Z)-2-(5-((8-hydroxy-2,3,6,7-tetrahydro-1H,5H-pyrido[3,2,1-ij]quinolin-9-yl)
methylene)-4-oxo-2-thioxothiazolidin-3-yl) acetic acid (HJRA) with
a twisted intramolecular charge transfer (TICT) property, which can
easily self-assemble into nonfluorescent nanoaggregates in aqueous
solution. However, HJRA nanoaggregates can selectively bind with serum
albumin proteins (HSA/BSA) in ∼100% PBS medium, thereby facilitating
the disassembly of nanoaggregates into monomers, exhibiting a clear
turn-on red fluorescent response toward HSA and BSA. Analysis of the
specific binding mechanism between HJRA and HSA using a site-selective
fluorescence displacement assay and molecular docking simulations
indicates that a variety of noncovalent interactions are responsible
for the disassembly of nanoaggregates with the concomitant trapping
of the HJRA monomer at site I in HSA, yielding a substantial red emission
caused by the inhibition of intramolecular rotation of HJRA probe
inside the hydrophobic cavity of HSA. The limit of detection (LOD)
determined by the 3σ/slope method was found to be 1.13 nM, which
is substantially below the normal HSA concentration level in healthy
urine, signifying the very high sensitivity of the probe toward HSA.
The comparable results and quick response toward quantification of
HSA in urine by HJRA with respect to the Bradford method clearly point
toward the superiority of this method compared to the existing ones
and may lead to biomedical applications for HSA quantification in
urine. It may also find potential application in live-cell imaging
of HSA.